Objectives of the meeting

This face-to-face meeting will focus on the recent expansion of scientific data and the current applications of next generation sequencing technologies for adventitious virus detection in biological products. This will include presentations on standardization and validation of the technical and bioinformatics steps involved in the NGS workflow and applications of different NGS strategies for characterization and safety evaluation of biologics, including human and animal vaccines, as well as gene therapy, and therapeutic products Current regulatory expectations will be discussed. The meeting will bring together representatives from industry, academia, contract research organizations, and international regulatory bodies for developing a scientific consensus regarding recommendations for using NGS for detection of adventitious viruses.

Scientific Committee

  • Arifa Khan U.S. FDA
  • Laurent Mallet EDQM
  • Pieter Neels IABS
  • Johannes Blümel PEI
  • Jean-Pol Cassart GSK Vaccines
  • Miia Jakava-Viljanen FIMEMA
  • Ivana Knezevic World Health Organization
  • Caine Logvinoff Sanofi
  • Jelle Matthijnssens KU Leuven
  • Egbert Mundt Boehringer Ingelheim
  • Michael Wall Health Canada

Organising Committee

  • Abigail Charlet, IABS, France